Semifluorinated alkane compositions for cleaning the skin

Abstract

The present disclosure is in the field of dermatological compositions and provides for the use of a composition comprising a semifluorinated alkane to cleanse skin, in particular for the removal of excess sebum or keratin. The disclosure also relates, in particular, to the use of the composition for cleansing skin comprising acne.

Description

[0001]DRM23P02PC1TITLE:^^SEMIFLUORINATED^ALKANE^COMPOSITIONS^FOR CLEANING^THE^SKINDescription BACKGROUND OF THE INVENTIONSkincare compositions and cleansers are provided as part of a management ortreatment strategy for improving the condition of the skin of a person suffering from acne, or a person with skin which is prone to acne, or acne outbreaks. Skincare compositions, or cleansers are typically aimed at addressing contributory factors associated the pathogenesis of acne, such as to provide relief, reduction or anamelioration of symptoms associated with acne, for example reduction ininflammation, sebum production and / or reduction of clogged pores, as well asproliferation of microorganisms on the skin.Excipients such as oxidants, alpha- or beta-hydroxy acids, polar solvents such asalcohols, surfactants, or the preservatives are frequently used, or found in skin cleanser products, or other products formulated for, or suitable for topical applicationto the skin. However, these may often have the effect of irritating or drying out theskin, or causing damage to the skin barrier over a period of long-term use, or in some cases, damaging / disrupting the natural skin microbiome.WO2012 / 16160179 A2 describes compositions comprising an active ingredient and asemifluorinated alkane for topical administration to the skin or skin appendage. Thesemifluorinated alkane is used as a carrier, to effect delivery and enhancedpenetration of drug compounds to the deeper layers of the skin.WO 2014 / 041055 A1 describes ophthalmic compositions comprising one or moresemifluorinated alkane for topical ophthalmic administration and use. It is describedthat it may help remove or wash away debris or discharge e.g. meibum from the eyelid, eye margins. Meibum is a fluid mixture secreted from meibomian glands of theeye to form part of the tear film. A specific use of semifluorinated alkanes to cleanseskin as such, that is, comprising sebaceous glands and / or hair follicles, and / or hyperkeratinized skin, or skin comprising inflammatory lesions or comedones (in the caseof acne) is however not disclosed.It is thus an object of the present invention to provide compositions for cleansing theskin, or for improving or ameliorating the condition of the skin of a person sufferingfrom acne, or with skin prone to acne. It is a further object of the present invention to provide compositions e.g. cosmetic, skincare or cleanser compositions which addresses the disadvantages of compositions in the art. Further objects of the invention will be clear on the basis of the following description of the invention, examples and claims. SUMMARY OF THE INVENTIONIn a one aspect, the invention relates to the use of a liquid composition comprising asemifluorinated alkane to cleanse skin, wherein the semifluorinated alkane is of the formula F(CF2)n(CH2)mH, wherein n is an integer selected from 4 to 8, and m is an integer selected from 2 to 10.In a further aspect, the invention provides for a liquid composition comprising asemifluorinated alkane, and one or more agents selected from the group consisting of (-)-alpha-bisabolol, α-pinene, caryophyllene, guaiazulene, chamomile oil and chamazulene. In a related aspect, said compositions may be used for topical application to the skin,for cleansing skin and / or for use in the treatment or amelioration of acneic skin, forexample wherein the cleansing comprises the removal of excess sebum from acneicskin. In yet further related aspect, the cleansing may comprise the removal, or thereduction of shed excess keratin from a hyperkeratinized skin. In yet a further aspect, the invention relates to a cosmetic or medical device comprising such liquid compositions such as defined in which is suitable, or adapted for the cleansing of, or the application of the liquid composition to the skin of a subject. DESCRIPTION OF THE DRAWINGSFigure 1 depicts the cleansing of skin, as demonstrated from administering acomposition comprising 1-perflurohexyloctane (F6H8) to the skin of a minipig; with left showing untreated area, and right showing the area that was effectively treated with 1-perflurohexyloctane (F6H8). DETAILED DESCRIPTIONThe present disclosure relates to, in a first aspect, the use of a liquid compositioncomprising a semifluorinated alkane to cleanse skin, wherein the semifluorinated alkane is of the formula F(CF2)n(CH2)mH, wherein n is an integer selected from 4 to 8, and m is an integer selected from 2 to 10. Semifluorinated alkanes are linear or branched alkanes where some of the hydrogen atoms are replaced by fluorine atoms having the chemical formula F(CF2)n(CH2)mH, wherein n and m are integers defining the number of carbons in the perfluorinatedhydrocarbon segment and non-fluorinated hydrocarbon segment, respectively. Thesemifluorinated alkane comprised in compositions according to the present disclosure is a semifluorinated alkane of formula F(CF2)n(CH2)mH, wherein n is an integer selected from 4 to 8 and m is an integer selected from 2 to 10. In other embodiments, the semifluorinated alkane is a semifluorinated alkane of formula F(CF2)n(CH2)mH, wherein n is an integer selected from 4 to 6 and m is an integer selected from 4 to 8. In a preferred embodiment, the semifluorinated alkanes used in the context of the present disclosure are preferably liquid at room temperature. A nomenclature which is also frequently used for linear semifluorinated alkanes designates the perfluorinated hydrocarbon segment as Fn and a non-fluorinated segment as Hm, i.e. FnHm, wherein F means a perfluorinated hydrocarbon segment, H means a non-fluorinated segment, and n and m define the number of carbon atoms of the respective segment. For example, F3H3 is used for perfluoropropylpropane, F(CF2)3(CH2)3H. This type of nomenclature is usually used for compounds having linear i.e. unbranched segments. Therefore, unless otherwise indicated, it should be assumed that F3H3 means 1-perfluoropropylpropane, rather than its structural isomers e.g. branched isomers such as 2-perfluoropropylpropane, 1- perfluoroisopropylpropane or 2-perfluoroisopropylpropane.In some embodiments of the composition, or composition used in the context of thepresent disclosure, the semifluorinated alkane is selected from F(CF2)4(CH2)5H(F4H5), F(CF2)4(CH2)6H (F4H6), F(CF2)4(CH2)8H (F4H8), F(CF2)4(CH2)10H (F4H10),F(CF2)6(CH2)6H (F6H6), F(CF2)6(CH2)8H (F6H8), and F(CF2)6(CH2)10H (F6H10). Insome embodiments, the composition comprises a semifluorinated alkane selectedfrom F4H5, F6H8, F4H8, or their structural isomers, and any mixture of thesesemifluorinated alkanes.The use according to the present disclosure may relate, in some aspects, to a liquidcomposition essentially consisting of a semifluorinated alkane for cleansing the skin.As used herein the term ‘a’ or ‘an’, or ‘the’ in relation to a semifluorinated alkane, orany other constituent part of the composition, such as an excipient does not excludethe plurality unless the context clearly indicates or requires otherwise. The terms ‘a’, ‘an’ and ‘the’ may be understood to correspond to ‘at least one’ or as ‘one or more’unless defined otherwise, or unless the context clearly indicates otherwise. Thus, theuse with respect to cleansing skin or any other use, or method as further describedherein may relate the use of a liquid composition comprising, or essentially consisting of a single semifluorinated alkane, or in some embodiments, a mixture of semifluorinated alkanes.The semifluorinated alkane F6H8, where F denotes a linear perfluorinated alkanesegment comprising 6 carbons and H denotes a linear and non-fluorinated alkanesegment of 8 carbon atoms, is also known as 1-perfluorohexyloctane and has thechemical formula F(CF2)6(CH2)8H. F6H8 is also a chemically and physiologically inert,water-insoluble liquid, and has a density of 1.34 g / cm3 at 25 °C and refractive index of1.3432 at 20 °C. In some embodiments, the semifluorinated alkane featured in a liquidcomposition, or a liquid composition as used according to the present disclosure is 1-perfluorohexyloctane (F6H8). In some embodiments, F6H8 as a liquid may be used byitself to directly to clean the skin, without any co-formulated components. As used herein, the term “consists” and related terms “consisting” or “consist” is to be understood as meaning that no other features, other than those prefaced by the term are present. In the context of compositions of the present disclosure, if any other constituent or component is present in the composition other than those prefaced by such term, then it is present only in trace or residual amounts such as to confer no technical advantage or relevance in respect of the object of the disclosure, such as may be further understood by the term ‘essentially” or “substantially” used in conjunction with these terms (e.g. ‘essentially consisting of”). In contrast, the term‘comprising”, or related terms “comprises” or “comprise” in the context ofcompositions, is to be understood as meaning that other features, other than those prefaced by the term may be present in the composition. In some embodiments, the composition comprises at least 50 to 99.9 wt % of thesemifluorinated alkane with respect to the total weight of the composition. In someembodiments, said semifluorinated alkane is 1-perfluorohexyloctane (F6H8).As understood and used herein, the term wt % or alternatively, “% (w / w)” and unlessotherwise indicated, refers to the amount of a component of a composition as a weight percentage in relation to the total weight of the composition with ‘w’ denoting weight.Further understood and as used herein, the term “% (w / v)” and unless otherwiseindicated, refers to percent weight by volume, namely the amount of a component of acomposition as a weight percentage in relation to the total volume of the compositionwith ‘w’ denoting weight and with “v” denoting volume; for example, 0.1% (w / v)refers to 1 mg / ml.The term % (v / v), or volume percent as used herein, and unless otherwise indicated,refers to the volume of a component of a composition in relation to the total volume of the composition. In other embodiments, the composition, or composition used according to the presentdisclosure, comprises 1-perfluorohexyloctane and 2-perfluorohexyloctane. In someembodiments, the composition comprises 1-perfluorohexyloctane and 2-perfluorohexyloctane, wherein the 2-perfluorohexyloctane is in an amount of 0.1 to 5%, with respect to the total amount (combined amount) of 1-perfluorohexyloctaneand 2-perfluorohexyloctane in composition. In some embodiments, the liquidcomposition essentially consists of 1-perfluorohexyloctane (F6H8). In otherembodiments, the liquid composition essentially consists of 1-perfluorohexyloctaneand 2-perfluorohexyloctane. The 2-perfluorohexyloctane in said embodiment may bepresent in the composition in an amount of up to 5 wt %, or up to 3 wt %, or up to 2wt %, or up to 1 wt %, up to 0.5 % wt % or up to 0.2 wt %, or between 0.2 to 3 wt %in respect with the total (combined) weight of 1-perfluorohexyloctane and 2-perfluorohexyloctane in the composition. In other embodiments, the 2-perfluorohexyloctane may be present in the composition in an amount of up to 5 %,or up to 3 %, or up to 2 %, or up to 1 %, up to 0.5 % or up to 0.2 %, or between 0.2 to3 % in respect with the total amount (combined amount) of 1-perfluorohexyloctaneand 2-perfluorohexyloctane in the composition, as determined by gaschromatography (e.g. as determined by gas chromatography with flame ionization detector (FID)). As understood herein, the term ‘essentially free’, or alternatively ‘substantially free’ or ‘component-free’ in reference to a composition constituent or component refers to the presence of said component in no more than trace amounts and that if present in trace amounts the component does not provide any technical contribution or material advantage to the composition. As mentioned above, the disclosure relates to the use of a liquid compositioncomprising a semifluorinated alkane as defined herein for cleansing skin. Thecleansing of skin, in one aspect may be understood as relating to a cosmetic use of acomposition as defined herein, e.g. as skincare or part of a skincare regimen. Said usemay comprise a step of topical application of the liquid composition to a skin surface,for example to remove, or to assist in the removal of any excess or accumulatedcellular materials, byproducts or secretions that are naturally produced by the skinand / or any one of its associated anatomical features, such as by the hair follicles,sweat glands, or sebaceous glands. This may include, but not be limited to dead orshed skin cells, shed particles of skin, keratin, sebum, sweat, or combinations thereof. The accumulation of such materials within the pores and glands of the skin may leadto, for example, the clogging of the sebaceous gland and / or hair follicles. The cloggingof sebaceous glands and / or hair follicles may further lead to inflammation, acneand / or keratosis pilaris, which also may have impact on physical appearance (e.g.redness of skin, or acne breakout). Notably, acne is a chronic inflammatory skindisease that can significantly influence psychological well-being, self-esteem, and social interactions.It has been found, as will be further detailed below, that through regular topicalapplication of a semifluorinated alkane, specifically F6H8, to skin which is affected bybrown spots or discolouration attributable to the presence of accumulated keratincells in the pores and glands of the skin, that these discolorations can be removed.According to some embodiments according to the present disclosure, the cleansing ofthe skin comprises the removal of excess sebum from the skin. In some embodiments, the cleansing of skin comprises the removal of excess keratin from the skin. In other embodiments, the cleansing of the skin comprises removal of excess sebum and keratin from the skin. In related embodiments, the use comprises the cleansing of sebum-obstructed and / or keratin-obstructed sebaceous glands, pores, or hair follicles of the skin. In some embodiments, the skin which is to be cleansed according to the present disclosure is preferably free of any cosmetic products (for example make-up) orresidues thereof. In other, and optional embodiments, the skin which is to be cleansedmay comprise or have a cosmetic product or make-up has been applied thereupon. Ina preferred embodiment, the skin is cleaned from comedogenic cosmetic residues, in particular from comedogenic cosmetic residues originating from one or more of oil- based cosmetics, (eyeliner, lipstick), sunscreens, moisturizers and / or medical ointments. The composition of the present disclosure, in particular when used as acosmetic or medical device, is effective to remove comedogenic cosmetic residues, inparticular it is effective to remove comedogenic cosmetic residues originating from one or more of oil-based cosmetics, (eyeliner, lipstick), sunscreens, moisturizers and / or medical ointments. Preferably, the composition for removing comedogeniccosmetic residues comprises or consists of 1-perfluorohexyloctane (F6H8). In some embodiments, in particular when the composition is used as a cosmetic ormedical device, the skin is to be cleansed according to the present disclosure fromsebum, lipid-rich dead skin cells (corneocyte debris), comedogenic cosmetic residues, environmental lipids and / or bacterial lipids. In some embodiments, the invention relates to a cosmetic or medical device, comprising a cosmetic or medical composition as defined above. In further embodiment of the present disclosure the compositions of the presentinventions are used as a cleansing agent or cleansing composition for removal oflipophilic cosmetic products, in particular for removal of long-wearing or waterproofcosmetic products, such as lipsticks, foundations or mascaras. Preferably, thecomposition for removing lipophilic cosmetic products comprises or consists of 1-perfluorohexyloctane (F6H8). In particular, a cleansing agent or cleansingcomposition essentially consisting of 1-perflurohexylocante is effective to removecosmetic products, in particular long-wearing or waterproof cosmetic products, suchas lipsticks, foundations or mascaras from the skin. The skin to which the presentcompositions according to the disclosure may be applied may be facial skin, i.e. skinlocated on the face of a subject. The composition may be topically applied to, or usedto cleanse the skin of the cheeks, forehead, nose, chin, or lips. The skin may be, insome embodiments, any facial skin, but not skin or tissues associated with the scalp,the eyes (e.g. eyelids, or eyelash line), or the ears. Moreover, as understood herein, skin does not relate to nail appendages in relation to the hands or feet; or mucosal tissue such as the inside of the nose, eyes, or mouth. In some embodiments, the skin to be cleansed or to which the composition may beapplied is any one or combination of skin located on the body of the subject, inparticular located on the face, neck, back, chest, upper arm, thigh or shoulders of asubject. In other embodiments, the skin to be cleansed or to which the composition may be applied is any one or combination of skin located on the body of a subjected selected from the face, shoulder, chest, and back (e.g. for use in treating acne), or selected from the upper arm, thighs, cheeks, or buttocks of a subject (e.g. for use in treating keratosis pilaris), or selected from the upper arm, and thighs of a subject (e.g.for use in treating keratosis pilaris). The subject as described according to the presentdisclosure is, moreover, preferably a human subject.As mentioned herein, in some embodiments, the cleansing of skin as described herein above is performed using a liquid composition comprising of a semifluorinated alkane as defined.In further aspect, the present disclosure relates to a liquid composition comprising asemifluorinated alkane, and one or more agents selected from the group consisting of(-)-alpha-bisabolol, α-pinene, caryophyllene, guaiazulene, chamomile oil andchamazulene. The semifluorinated alkane may be a semifluorinated alkane (or mixture of semifluorinated alkanes) as described in any one or combination of embodiments described herein. In one embodiment, the semifluorinated alkane is of the formula F(CF2)n(CH2)mH, wherein n is an integer selected from 4 to 8, and m is aninteger selected from 2 to 10; or is 1-perfluorohexyloctane.(-)-alpha-bisabolol (CAS no. 23089-26-1, also known as levomenol, or (2S)-6-methyl-2-[(1S)-4-methylcyclohex-3-en-1-yl]hept-5-en-2-ol) is a monocyclic sesquiterpenealcohol. α-pinene, also known as alpha-pinene (CAS no. 80-56-8 for the racemate), is amonoterpene compound. It has two enantiomers, respectively with the chemicalnames (1S,5S)-2,6,6-trimethylbicyclo[3.1.1]hept-2-ene ((-)-α-pinene), or itsenantiomer (1R,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-2-ene ((+)-α-pinene). Acomposition comprising α-pinene as understood herein may refer to a compositioncomprising any one of the enantiomers, the racemate compound, or any ratio of amixture of the two enantiomers. Caryophyllene, which may also be known as beta-caryophyllene (CAS no.87-44-5) is a bicyclic sesquiterpene.Chamazulene (CAS no. 529-05-5) has the chemical name 7-Ethyl-1,4-dimethylazulene. Guaiazulene (CAS no.489-84-9) has the chemical name 1,4-dimethyl-7-isopropylazulene and is a bicyclic sesquiterpene. In some embodiments, the liquid compositions according to the present disclosure comprise of a semifluorinated alkane as defined herein (e.g. F6H8) and (-)-alpha-bisabolol, guaiazulene, chamazulene or chamomile oil.In some embodiments, the composition may comprise of, or essentially consist of asemifluorinated alkane (e.g. F6H8), and (-)-alpha-bisabolol. The amount of (-)-alpha-bisabolol featured in the composition may be, in some embodiments, up to 1.5 %(w / v), or up to 1.0 % (w / v), or may be in the range of 0.01 to 1.5 % (w / v); orbetween 0.01 to 1.0 % (w / v), or in the range of 0.01 to 0.5% (w / v), or in the range of0.2 to 1.0 % (w / v), or in the range of 0.2 to 0.5 % (w / v).In some embodiments, the composition may comprise of, or essentially consist of a semifluorinated alkane (e.g. F6H8), and chamazulene. The amount of chamazulene featured in the composition according to the present disclosure may be up to 0.2 %(w / v), or in the range of 0.01 to 1.0 % (w / v), or in the range of 0.1 to 0.5 % (w / v) , orin the range of 0.1 to 0.2 % (w / v). In some embodiments, the composition may comprise of, or essentially consist of asemifluorinated alkane (e.g. F6H8), and guaiazulene. The amount of guaiazulenefeatured in the composition according to the present disclosure may be up to 0.8 %(w / v), or in the range of 0.1% (w / v) to 0.8 % (w / v), or between 0.1 to 0.5 % (w / v), orin the range of 0.2 to 0.5 % (w / v).In some embodiments, the composition may comprise of, or essentially consist of a semifluorinated alkane (e.g. F6H8), and chamomile oil. The amount of chamomile oilfeatured in the composition according to the present disclosure may be up to 1.0 %(w / v), or up to 0.5 % (w / v), or up to 0.25 % (w / v), or in the range of 0.01 % to 1.0 %(w / v), or in the range of 0.1 to 0.5 % (w / v), or in the range of 0.05 to 0.2 % (w / v), orin the range of 0.1 to 0.25 % (w / v).In some embodiments, the composition may comprise of, or essentially consists of asemifluorinated alkane (e.g. F6H8), and chamomile oil. The amount of chamomile oilfeatured in the composition according to the present disclosure may be up to 10 %(w / v), or up to 5 % (w / v), or up to 2.5 % (w / v), or up to 1.5 % (w / v), or up to 1.0 % (w / v), or up to 0.5% (w / v), or up to 0.25% (w / v), or in the range of 0.01% to 1.0% (w / v), or in the range of 0.5 to 10 % (w / v), or in the range of 0.5 to 5 % (w / v), or in the range of 0.5 to 2.5 % (w / v), or in the range of 0.5 to 1.5 % (w / v), or in the range of 0.5to 1 % (w / v), or in the range of 0.1 to 0.5 % (w / v), or in the range of 0.05 to 0.2 %(w / v), or in the range of 0.1 to 0.25% (w / v). In related embodiments, the compositionis a solution comprising of, or essentially consisting of chamomile oil in 1-perfluorohexyloctane (F6H8) and optionally, 2-perfluorohexyloctane in the relativeamounts as disclosed herein.In some embodiments, the composition comprises of, or essentially consists of asemifluorinated alkane (e.g. F6H8), and α-pinene. The amount of α-pinene featured inthe composition may be, in some embodiments, up to 1.0 % (w / v), or may be in therange of 0.001 % to 1.0 % (w / v); or between 0.01 to 0.5 % (w / v), or between 0.1 to0.5 % (w / v), or between 0.2 to 0.5 % (w / v).In some embodiments, the composition may comprise of, or essentially consist of a semifluorinated alkane (e.g. F6H8), and caryophyllene. The amount of caryophyllenefeatured in the composition may be, in some embodiments, up to 6 % (w / v), or up to5 % (w / v), or up to 2 % (w / v), or may be in the range of 0.01 % (w / v) to 2.0 % (w / v);or between 0.01 to 1.0 % (w / v), or between 0.1 to 0.5 % (w / v), or between 0.2 to 0.5% (w / v).The liquid compositions comprising these one or more agents selected from thegroup consisting of (-)-alpha-bisabolol, α-pinene, caryophyllene, guaiazulene, chamomile oil and chamazulene, as described above may be used for cleansing skin,or for any one of the uses or methods as described herein.In yet a further aspect, the present disclosure relates to a liquid compositioncomprising a semifluorinated alkane and chamomile oil. The semifluorinated alkanemay be a semifluorinated alkane (or mixture of semifluorinated alkanes) as described in any one or combination of embodiments described herein. In one embodiment, the semifluorinated alkane is of the formula F(CF2)n(CH2)mH, wherein n is an integer selected from 4 to 8, and m is an integer selected from 2 to 10. In anotherembodiment, the semifluorinated alkane is 1-perfluorohexyloctane (F6H8).Chamomile oil is an essential oil derived from the chamomile plant matricaria^recutita (also may be referred to as matricaria^chamomilla, or chamomilla^recutita).Other names for chamomile oil include blue chamomile, or German chamomile. Whenapplied to the skin in combination with a semifluorinated alkane carrier, thechamomile oil may be useful to help soothe any inflammation, or redness of the skine.g. skin afflicted with acne.Preferably, the chamomile oil as used is obtained from the steam distillation of thechamomile plant. In some embodiments, the composition, or composition used asdescribed herein, comprises up to 10 %, 5 % 2.5% 1.0, 0.5%, 0.25 %, or 0.1% (w / v)chamomile oil. In some embodiments, the composition comprises between 0.1 to 10%, or 0.5 to 5%, or 0.5 to 2.5%, or 0.5 to 1.5%, or between 0.05 to 1.0 % (w / v) chamomile oil. In a preferred embodiment, the composition, or composition used as described herein, comprises about 0.25%, or 0.5%, or 0.75%, or 1%, or 1.5%, or 2.5%, or 5% orabout 10 % (w / v) chamomile oil.Said liquid compositions comprising chamomile oil may be used for cleansing skin inaccordance any one of the embodiments as described herein. Said liquid compositionscomprising chamomile oil may also be in any of the other uses, or methods as described herein.These liquid compositions, and any described heretofore or with respect to any of theuses described according to the present disclosure may further comprise a non-polarexcipient. In some embodiments, a liquid composition comprising a semifluorinatedalkane, optionally an agent selected from the group consisting of (-)-alpha-bisabolol,α-pinene, caryophyllene, guaiazulene, chamomile oil and chamazulene as definedherein further comprises a non-polar excipient.The non-polar excipient is preferably a liquid excipient, which is fully miscible withthe semifluorinated alkane. The non-polar excipient may be a hydrocarbon. In some embodiments, the non-polar excipient is selected from a C10 to C40 branched, saturated hydrocarbon a C10-C40 unbranched, saturated hydrocarbon, and mixtures thereof. In some embodiments, the non-polar excipient is squalane. In some other embodiments, the non-polar excipient that is fully miscible with the semifluorinated alkane is a medium chain triglyceride. In some embodiments, the composition according to the present disclosurecomprises up to 50 % (v / v) of squalane with respect to the total volume of thecomposition. In some embodiments, the compositions, as used according to thepresent disclosure comprises between 0.01 to 50 % (v / v) of squalane, with respect tothe total volume of the composition. In some embodiments, the compositioncomprises up to 10 % (v / v) of squalane or between 0.01 % (v / v) to 10 % (v / v) ofsqualane. In some embodiments, the compositions, used as a cleansing agent or in accordance with any other uses or any other methods as described herein do not comprise of akeratolytic agent, preferably wherein the keratolytic agent is selected from the groupconsisting of an alpha-hydroxy acid, a beta-hydroxy acid, urea and any combinations thereof. In some further embodiments, the physical form of the composition is not an ointment. An ointment is a semi-solid preparation, which for example when exposed to body temperature, softens or melts. In yet further embodiments, the composition is free of any one, or a combination of:- a solid thickening agent, preferably wherein the solid thickening agent is selectedfrom plant waxes, animal waxes, petroleum derived waxes, solid and semisolid triglycerides, C12-24 fatty acids, C8-18 glycerides, fatty alcohols, fatty alcohols derivatives and any combinations thereof;- an oxidant, e.g. a peroxide, such as benzoyl peroxide, or hydrogen peroxide;- an alpha-hydroxy acid, preferably selected from the group consisting of citric acid;glycolic acid, hydroxycaprylic acid, hydroxycapric acid, lactic acid, malic acid, mandelic acid, phytic acid, and tartaric acid;- a beta-hydroxy acid, preferably selected from the group consisting of salicylic acid,and sodium salicylate;- urea- a polar solvent, preferably selected from the group consisting of ethyl acetate,acetone, an alcohol (e.g. ethanol, isopropanol) and DMSO;- water;- a preservative, preferably selected from the group consisting of benzalkoniumchloride, chlorhexidine, methylisothiazolinone, methylchlorisothiazolinone, phenoxyethanol, triclosan; and- a surfactant, preferably selected from the group consisting of polysorbate (e.g.polysorbate 60), ceteareth, e.g. any one of ceteareth-6 to ceteareth-25), polyethylene glycol fatty acid esters (e.g. Tefose®63), sucrose esters (e.g. sucrose stearate, sucrose ester SP70). Polysorbates are polyoxyethylene sorbitan monostearates. Ceteareth-6 to ceteareth- 25 may also be known by their commercial names Cremophor®-A6, to Cremophor®-A25) and are polyoxyethylene ethers of cetyl and / or stearyl alcohols. Tefose® 63 is amixture of PEG-6 stearate, ethylene glycol palmitostearate and PEG-32 stearate. In some alternative embodiments, the compositions, used as a cleansing agent or in accordance with any other uses or any other methods as described herein may comprise an alcohol, such as isopropanol or ethanol.Keratolytic agents are used cosmetically and to treat pathological cornificationdisorders such as hyperkeratosis, and trigger or cause keratolysis, namely a processof loosening, detaching or shedding of the outmost layer of the skin, the stratumcorneum. Keratolytic agents improve the appearance of the skin, minimizes dandruff,and also help other topical medications to penetrate the skin better. Typicalkeratolytic agents include alpha-hydroxy acids (e.g. citric acid; glycolic acid, hydroxycaprylic acid, hydroxycapric acid, lactic acid, malic acid, mandelic acid, phyticacid, tartaric acid), beta-hydroxy acids (e.g. salicylic acid, sodium salicylate), azelaicacid, urea, allantoin, trichloroacetic acid, resorcinol, retinoids (e.g. retinoic acidacitretin, adapalene, tretinoin, isotretinoin, motretinide, tazarotene) benzoyl peroxide. Surprisingly, is was found that the compositions of the present disclosure show keratolytic properties and can be used as keratolytic agents, preferably in lieu of, or in the absence of keratolytic agents, such as described above, e.g. water soluble keratolytic compounds, such as water soluble acids, or compounds selected from thegroup consisting of alpha-hydroxy acids, beta-hydroxy acids, azelaic acid, urea,allantoin, trichloroacetic acid, resorcinol, retinoids and peroxides. Preferably, thecompositions of the present disclosure are water-free, keratolytic compositions. Saidcompositions may be used, for example, to break down, or disassemble keratinstructures or layers of the skin, or assist in the break down or disassembly of keratinic structures or layers of the skin, in particular in hyperkeratinized areas ofthe skin such as psoriatic plaques, or in skin affected by hyperkeratosis.. In someembodiments, the compositions are water-free keratolytic compositions which maybe used to treat pathological cornification disorders of the skin, or hyperkeratosis ofthe skin, for example psoriasis, psoriatic plaques, acne, or eczema or of the follicles ofthe skin, such as keratosis pilaris.Excipients such as oxidants, alpha- or beta-hydroxy acids, polar solvents such asalcohols, surfactants, or the preservatives such as noted above are frequently found inskin cleanser products, or other products formulated for, or suitable for topicalapplication to the skin, but may have an effect of, for example: irritating or drying out the skin, causing damage to the skin barrier over a period of long term use, or damaging / disrupting the natural skin microbiome. The compositions of the present disclosure may be used to cleanse skin effectively while avoiding at least some these potential adverse effects on the skin.The liquid compositions as described herein and for use according to the presentdisclosure are preferably solutions. The term “solution” may be used interchangeablywith the term ‘a clear solution” and as understood herein, refers to a liquid solution inwhich any solutes are fully dissolvable or dissolved under room temperatureconditions i.e. between 15 and 25 °C. A clear solution does not comprise of anyparticulate or solid phase components and preferably has a refractive index approximate to that of water (i.e.1.333) or else a refractive index proximal to that of the solvent or mixture of solvents at room temperature.Where at least two liquids are combined and mixed together i.e. a semifluorinatedalkane and any one or more of a non-polar excipient which may also be in the form ofa liquid (e.g. at room temperature), or chamomile oil, or an agent selected from thegroup consisting of (-)-alpha-bisabolol, α-pinene, caryophyllene, guaiazulene,chamomile oil and chamazulene, the resulting composition may also be in the form ofa clear solution, wherein the components that are combined with the semifluorinatedalkane are fully miscible with the semifluorinated alkane to form a single liquid phase. In this context, the semifluorinated alkane may also be more than one semifluorinated alkane, for example 1-perfluorohexyloctane and 2- perfluorohexyloctane.The composition in some embodiments have a dynamic viscosity at roomtemperature of between 1 and 4 mPas. The compositions are preferably of lowviscosity as opposed to for example, a composition which is in the form of anointment such that the liquid composition may be easily dispensable and / orspreadable onto a surface of the skin.In some embodiments, the compositions as used, or provided herein essentially consists of 1-perfluorohexyloctane, (-)-alpha-bisabolol, and optionally 2-perfluorohexyloctane, and further optionally, squalane. In some embodiments, thecompositions as used or provided herein essentially consists of 1-perfluorohexyloctane, chamomile oil, and optionally, 2-perfluorohexyloctane, andfurther optionally, squalane. In some embodiments, the composition as used or provided herein essentially consists of: i) the semifluorinated alkane and (-)-alpha-bisabolol;ii) the semifluorinated alkane and (-)-alpha-bisabolol, 2-perfluorohexyloctane, and optionally, squalane; iii) the semifluorinated alkane and chamomile oil; oriv) the semifluorinated alkane and chamomile oil, 2-perfluorohexyloctane,and optionally, squalane. In other embodiments, the composition as used or provided herein essentially consists of: i) 1-perfluorohexyloctane and (-)-alpha-bisabolol;ii) 1-perfluorohexyloctane, (-)-alpha-bisabolol and 2-perfluorohexyloctane, and optionally, squalane; iii) 1-perfluorohexyloctane and chamomile oil; oriv) 1-perfluorohexyloctane, chamomile oil, 2-perfluorohexyloctane, andoptionally, squalane. In a further preferred embodiment, the composition or composition as used or provided herein essentially consists of 1-perfluorohexyloctane, chamomile oil, and optionally 2-perfluorohexyloctane.The yet further embodiments, the compositions, or the compositions as used orprovided for use or methods as described herein essentially consists of:- 1-perfluorohexyloctane, up to 1.0 % (w / v) (-)-alpha-bisabolol (or up to 0.20 %(w / v) (-)-alpha-bisabolol), and optionally, up to 3 % 2-perfluorohexyloctane inrespect to the total amount of 1-perfluorohexyloctane and 2-perfluorohexyloctane inthe composition; or- 1-perfluorohexyloctane, up to 1.0 % (w / v) chamomile oil (or up to 0.5 % (w / v), orup to 0.20 % (w / v) chamomile oil), and optionally, up to 3 % 2-perfluorohexyloctanein respect to the total amount of 1-perfluorohexyloctane and 2-perfluorohexyloctanein the composition; or- 1-perfluorohexyloctane, up to 1.0 % (w / v) α-pinene (or up to 0.20 % (w / v) α-pinene), and optionally, up to 3 % 2-perfluorohexyloctane in respect to the totalamount of 1-perfluorohexyloctane and 2-perfluorohexyloctane in the composition; or- 1-perfluorohexyloctane, up to 1.0 % (w / v) caryophyllene (or up to 0.20 % (w / v)caryophyllene), and optionally, up to 3 % 2-perfluorohexyloctane in respect to thetotal amount of 1-perfluorohexyloctane and 2-perfluorohexyloctane in thecomposition; or- 1-perfluorohexyloctane, up to 1.0 % (w / v), or up to 5.0 % (w / v) guaiazulene (or upto 0.50 % (w / v) guaiazulene), and optionally, up to 3 % 2-perfluorohexyloctane inrespect to the total amount of 1-perfluorohexyloctane and 2-perfluorohexyloctane inthe composition; or- 1-perfluorohexyloctane, up to 1.0 % (w / v) chamazulene (or up to 0.20 % (w / v)chamazulene), and optionally, up to 3 % 2-perfluorohexyloctane in respect to thetotal amount of 1-perfluorohexyloctane and 2-perfluorohexyloctane in thecomposition; or- 1-perfluorohexyloctane and optionally, up to 3 % 2-perfluorohexyloctane in respectto the total amount of 1-perfluorohexyloctane and 2-perfluorohexyloctane in thecomposition; or- 1-perfluorohexyloctane, up to 1.0 % (w / v) (-)-alpha-bisabolol, up to 10 % (v / v)squalane, and optionally, up to 3 % 2-perfluorohexyloctane in respect to the totalamount of 1-perfluorohexyloctane and 2-perfluorohexyloctane in the composition; or- 1-perfluorohexyloctane, up to 1.0 % (w / v) chamomile oil, up to 10 % (v / v) squalaneand optionally, up to 3 % 2-perfluorohexyloctane in respect to the total amount of 1-perfluorohexyloctane and 2-perfluorohexyloctane in the composition; or- 1-perfluorohexyloctane, up to 1.0 % (w / v) (-)-alpha-bisabolol (or up to 0.2 % (w / v)of (-)-alpha-bisabolol), up to 10 % (v / v) squalane, and optionally, up to 3 % 2-perfluorohexyloctane in respect to the total amount of 1-perfluorohexyloctane and 2-perfluorohexyloctane in the composition; or- 1-perfluorohexyloctane, up to 1.0 % (w / v) caryophyllene (or up to 0.2 % (w / v) ofcaryophyllene), up to 10 % (v / v) squalane, and optionally, up to 3 % 2-perfluorohexyloctane in respect to the total amount of 1-perfluorohexyloctane and 2-perfluorohexyloctane in the composition; or- 1-perfluorohexyloctane, up to 1.0 % (w / v) chamomile oil (or up to 0.2 % (w / v) ofchamomile oil), up to 10 % (v / v) squalane, and optionally, up to 3 % 2-perfluorohexyloctane in respect to the total amount of 1-perfluorohexyloctane and 2-perfluorohexyloctane in the composition; or- 1-perfluorohexyloctane, up to 5.0 % (w / v) guaiazulene (or up to 1.0 % (w / v)guaiazulene, or up to 0.5 % (w / v) of guaiazulene), up to 10 % (v / v) squalane, andoptionally, up to 3 % 2-perfluorohexyloctane in respect to the total amount of 1-perfluorohexyloctane and 2-perfluorohexyloctane); or- 1-perfluorohexyloctane, up to 10 % (v / v) squalane, and optionally, up to 3 % 2-perfluorohexyloctane in respect to the total amount of 1-perfluorohexyloctane and 2-perfluorohexyloctane in the composition.These and other embodiments of the composition as described herein may be usedfor cleansing skin. In a related embodiment, the cleansing of the skin comprises theremoval of excess sebum from acneic skin. As understood herein, acneic skin refers toskin which is afflicted with acne.Acne may be characterized by the formation of inflammatory lesions or comedoneson the skin. One of the main factors associated with the pathogenesis of acne is the excess production of natural oils, or sebum by the sebaceous gland, which may lead tothe plugging, or clogging of a follicle or a pore. This may lead to an accumulation ofsebum, optionally in combination with shed keratin and / or dead cellular debris in thefollicle or pore. Under these conditions, a colonization, or a proliferation of bacteria,such as commensal bacterial typically found on the skin, in particular cutibacteriumacnes (also known as propionobacterium acnes) may occur, leading to, or causinginflammation. The inflammation may lead to the formation of lesions, which in turn can also result in scarring, depending on the severity of grade.In some embodiments in relation to the use of the composition according to thepresent disclosure to cleanse skin, the use comprises the removal of sebum and / orshed keratin and / or cellular debris from the skin, or from the hair follicles or thepores of the skin. In related embodiments, the use comprises the cleansing of sebum-obstructed and / or keratin-obstructed sebaceous glands, pores, or hair follicles of the skin. In other related embodiments, the use comprises a removal of excess sebum thatis obstructing hair follicles on acneic skin. The cleansing may also comprise theremoval, or the reduction of shed excess keratin from the skin. In some embodiments,the cleansing, or use comprises the removal of shed excess keratin from ahyperkeratinized area of the skin, e.g. areas of the skin affected by hyperkeratosis. Ahyperkeratinized area of the skin may be understood generally as being an area of theskin where keratin and / or dead cell debris has accumulated, e.g. in hair follicles,which may also be blocking the openings of the follicles. This may lead to theappearance of small, raised bumps (usually of or around the hair follicle) and / or appearance of coloured spots in these areas of the skin. Such condition especially ifwide-spread or persistent on the skin may be classified as the skin conditionkeratosis pilaris.In some embodiments, a method of removing excess sebum, keratin and / or generalcellular debris with the composition may comprise a step of topically applying thecomposition to the skin, followed by subsequent step of applying an absorbent meansonto the skin. In some embodiments, the application of the absorbent means at leastpartially removes excess sebum, keratin, and / or general cellular debris from the skin,while concomitantly removing any remains of the composition.In a further aspect, the liquid compositions described herein as such may be providedfor use as a medicament. In further aspect of the disclosure, the liquid compositionaccording to the present disclosure is for use in the treatment of acne or is used in amethod of treating acne. Such use, or method is based on topical administration of thecomposition to the skin of a subject. In some embodiments, the skin is facial skin, orskin located in the face, on the neck, back, chest, or shoulders of a subject.Preferably, the subject is a human. The subject may be suffering from acne, acnevulgaris, folliculitis, or from keratosis pilaris. In some embodiments a compositionaccording to the present disclosure is for use in the treatment of acne vulgaris,folliculitis, or keratosis pilaris. In other embodiments, a composition according to thepresent disclosure is for cleansing, or for the use in the treatment of the skin of a subject suffering from acne, or acne vulgaris, folliculitis, or keratosis pilaris, or any combination thereof; wherein the skin is selected from facial skin, skin located on the face, on the neck, back, chest, shoulders and any combination thereof.Acne vulgaris is a chronic condition of acne, or in other words, acne which isoccurring over a longer period, or else persistently on an area of the skin. Folliculitisis the inflammation of one or more hair follicles, due in an infection of one or morehair follicles by a pathogenic microorganism such as a bacteria like staphylococcalbacterium (e.g. staphylococcus aureus), or pseudomonas aeruginosa. Folliculitis maypresent symptomatically as inflamed or itchy skin, or result in the appearance ofbumps or pimple arising from the affected hair follicle(s).In alternative and further aspects of the present disclosure, the liquid compositions asdescribed herein are used for the topically treating, ameliorating, or relievinginflamed areas of the skin. In yet a further alternative aspect of the present disclosurerelates to the use of a composition as defined herein as a chemical peel, as a non- water soluble / non-aqueous keratolytic agent, or for keratolysis of the skin. Achemical peel as understood herein is a composition which may function as anexfoliant to remove dead cells or excess keratin from the skin. Chemical peels in theart may comprise keratolytic agents such as acids, or enzymes to assist in thebreakdown of dead skin cells or debris. However, the compositions as defined hereinabove are, in a preferred embodiment, are free of such other excipients.Any of the liquid compositions, or uses with respect to any of the liquid compositionsas described herein may be applicable in the context of methods of cleaning the skin,or with respect to methods of treating, preventing, ameliorating any of the diseases orconditions of the skin as described herein. Also provided for within the context of the present disclosure is the use of any of the compositions as described herein in the manufacture of a skin-cleaning (cosmetic) composition, or else in the manufacture of a medicament for treating, relieving or ameliorating any of the conditions or diseases of the skin according to any one or combination of the embodiments as describe herein.The use of the liquid compositions according to the present disclosure comprises thetopical application of the liquid composition to the surface of the skin. The topicalapplication may comprise a step of topically applying the composition to the skin bymeans of a device, wherein the device is selected from a spray, a roll-on applicator, a sponge, and a wipe.As a subsequent or simultaneous step to applying the liquid composition to the skin,the composition may be in some embodiments, be further rubbed or massaged intothe skin, or dispersed or spread across the surface of the skin, for example byapplication of manual friction, such as by the fingers of a subject, or by means of adevice such as roll-on applicator, sponge, or a wipe. As a further subsequent step, an absorbent means may, in some embodiments beapplied onto the skin. Said step may comprise, or may consist of a step of removingthe composition or any remains of the applied composition from the skin with theabsorbent means. The absorbent means may be a sponge, a cloth, a wipe or anyfibrous non-woven, or woven material which is suitable or capable of absorbing the liquid composition and / or any associated materials such as the excess sebum and / or shed keratin, cellular debris from the skin. A subject may for example, after a liquid composition is applied to target area of the skin, then remove any remaining or residual liquid from their skin by applying a wipe or a cloth, i.e. by wiping or absorbing the composition away. In some embodiments, an incubation period may be provided between the step oftopical application of the liquid composition to the skin and optional massaging orrubbing, or dispersing of the composition across the surface of the skin, and the stepof removing the applied composition, or the remains of the applied composition, andoptionally excess sebum and / or shed keratin and / or cellular debris from the skin.The incubation period refers to period of time elapsing between application and removal of the (remains of) the composition. In some embodiments, this may at least 5 seconds, 10 seconds, or at least 20 seconds, or at least 30 seconds, or at least a minute. In some embodiments, there is no incubation period, i.e. the liquid composition is simply applied to the skin as such.In one embodiment, the present disclosure is directed to a method of treating orcleansing the skin of a subject suffering from acne, acne vulgaris, folliculitis, keratosispilaris or any combination thereof, comprising the steps of i.) topically applying acomposition as defined herein to the skin of the subject; and optionally, ii.) removingthe (remains of) the applied composition from the skin with an absorbent means. Themethod may in some embodiments comprise of an incubation period between steps i.) and ii). An incubation period may be for example at least 5 seconds, or at least 10 seconds, or at least 20 seconds, or at least 30 seconds, or at least a minute.Concomitantly with step ii.), any one or combination of the applied composition (e.g.remains thereof), excess keratin and / or excess sebum and / or cellular debris may be removed from the skin. A yet further aspect of the present disclosure relates to a cosmetic or medical device comprising a liquid composition as defined herein which is suitable, or adapted forthe cleansing of, or the application of the liquid composition to the skin of a subject.The cosmetic or medical device may be provided for any of the uses or methods asdefined herein. In particular, the device may be adapted for applying the liquidcomposition to the skin of a subject, e.g. a human subject suffering from acne, acne vulgaris, folliculitis, keratosis pilaris or a combination of these conditions. In some embodiments, the cosmetic or medical device is a wet wipe, a spongeapplicator, or a roll-on applicator. The device in some embodiments may be a woven,or non-woven substrate (e.g. a wet-wipe) comprising any one or combination ofcotton, viscose, lyocell, or a cellulosic fibre, that is pre-wetted with a liquid composition as defined herein.In some embodiments, the cosmetic or medical device is also adapted for removingany of the applied composition or the remains of the applied composition along withexcess keratin and / or excess sebum and / or cellular debris from the skin. In the caseof a wipe, for example, this may function to apply the liquid composition to the skin,but also with the actuation or use of the wiping action across skin, this may removeany excess keratin and / or excess sebum and / or cellular debris along with any of theapplied liquid compositions or remnants thereof.As a further aspect, the present disclosure also relates to a kit comprising a containerfor holding a composition as defined according to any of the embodiments orcombination of embodiments described herein, and an application means forapplying the composition to the skin of a subject. In one embodiment, the applicationmeans is a wet wipe that is pre-wetted with the liquid composition, preferablywherein the wet wipe is adapted for a user to rub, or massage the composition onto the skin. In other embodiments, the application means is a sponge applicator. The sponge applicator is preferably suitable for, or adapted for administering, massaging, orrubbing the composition into the skin. In some embodiments, the sponge applicator isadapted for application, e.g. massaging, or rubbing the composition into the affectedareas of the skin, such as hyperkeratinized areas of the skin.In some embodiments, the kit may further comprise a means for removing thecomposition, or the remains of the composition in combination with excess keratinand / or excess sebum from the skin. The means for removing the composition and / orremains of the composition in combination with excess keratin and / or excess sebumis in some embodiments, an absorbent substrate or material, for example a dry wipeor a pad, or an absorbent means such as described above. As understood herein, saidmeans is not the same means for applying the composition to the skin, but aseparately provided part of the kit. The substrate or absorbent means may be forexample a woven, or non-woven substrate comprising any one or combination of cotton, viscose, lyocell, or a cellulosic fibre. In some embodiments, where thecomposition is provided in the form of a pre-wetted substrate, e.g. a wet wipe, thesubstrate of the means for removing the composition and / or composition plus excesskeratin, cellular debris, sebum etc may be the same type of substrate as used thesubstrate for applying the composition to the skin, albeit dry.The present disclosure further relates to the following embodiments :1. Use of a liquid composition comprising a semifluorinated alkane to cleanseskin, wherein the semifluorinated alkane is of the formula F(CF2)n(CH2)mH, wherein n is an integer selected from 4 to 8, and m is an integer selected from 2 to 10.2. The use according to item 1, wherein the composition further comprises oneor more agents selected from the group consisting of (-)-alpha-bisabolol, α- pinene, caryophyllene, guaiazulene, chamomile oil, and chamazulene.3. The use according to item 1 or 2, wherein the composition compriseschamomile oil.4. The use according to item 3, wherein the composition comprises up to 1.0- %(w / v) chamomile oil.5. The use according to any preceding item, wherein the semifluorinated alkaneis selected from F(CF2)4(CH2)5H (F4H5), F(CF2)4(CH2)6H (F4H6),F(CF2)4(CH2)8H (F4H8), F(CF2)4(CH2)10H (F4H10), F(CF2)6(CH2)6H (F6H6),F(CF2)6(CH2)8H (F6H8), and F(CF2)6(CH2)10H (F6H10).The use according to any preceding item, wherein the composition comprisesat least 50 to 99.9 wt % of the semifluorinated alkane.The use according to any preceding item, wherein the semifluorinated alkaneis 1-perfluorohexyloctane (F6H8).The use according to item 7, wherein the composition further comprises 2-perfluorohexyloctane in an amount of 0.1 to 5 % with respect to the total amount (combined amount) of 1-perfluorohexyloctane and 2- perfluorohexyloctane in the composition.The use according to any preceding item, wherein the composition furthercomprises a non-polar excipient, preferably wherein the non-polar excipient is a liquid excipient fully miscible with the semifluorinated alkane.The use according to item 9, wherein the non-polar excipient is selected fromC10-C40 branched, saturated hydrocarbons and C10-C40 unbranched, saturated hydrocarbons.The use according to items 9 or 10, wherein the non-polar excipient issqualane, optionally wherein the composition comprises up to 50 % (v / v) of squalane.The use according to any preceding item, wherein the composition is asolution.The use according to any preceding item, wherein the composition has adynamic viscosity at room temperature of between 1 and 4 mPas.The use according to any preceding item, wherein the composition does notcomprise a keratolytic agent selected from the group consisting of an alpha-hydroxy acid, a beta-hydroxy acid, urea and any combinations thereof.The use according to any preceding item, wherein the composition is not anointment and / or wherein the composition is free of any one, or combination of:- a solid thickening agent, preferably wherein the solid thickening agent isselected from plant waxes, animal waxes, petroleum derived waxes, solid and semisolid triglycerides, C12-24 fatty acids, C8-18 glycerides, fatty alcohols, fatty alcohols derivatives and any combinations thereof;- an oxidant, e.g. a peroxide, such as benzoyl peroxide, or hydrogen peroxide;- an alpha-hydroxy acid, preferably selected from the group consisting of citricacid; glycolic acid, hydroxycaprylic acid, hydroxycapric acid, lactic acid, malicacid, mandelic acid, phytic acid, and tartaric acid;- a beta-hydroxy acid, preferably selected from the group consisting of salicylicacid, and sodium salicylate; -urea;- a polar solvent, preferably selected from the group consisting of ethylacetate, acetone, an alcohol (e.g. ethanol, isopropanol) and DMSO;- water;- a preservative, preferably selected from the group consisting ofbenzalkonium chloride, chlorhexidine, methylisothiazolinone, methylchlorisothiazolinone, phenoxyethanol, triclosan;- a surfactant, preferably selected from the group consisting of polysorbate(e.g. polysorbate 60), ceteareth, (e.g. any one of ceteareth-6 to ceteareth-25), polyethylene glycol fatty acid esters (e.g. Tefose®63), and sucrose esters (e.g. sucrose stearate, sucrose ester SP70).The use according to any preceding item, wherein the composition essentiallyconsists of:v) the semifluorinated alkane and (-)-alpha-bisabolol;vi) the semifluorinated alkane and (-)-alpha-bisabolol, 2-perfluorohexyloctane, and optionally, squalane;vii) the semifluorinated alkane and chamomile oil; orviii) the semifluorinated alkane and chamomile oil, 2-perfluorohexyloctane,and optionally, squalane.The use according to any preceding item, wherein the composition essentiallyconsists of:v) 1-perfluorohexyloctane and (-)-alpha-bisabolol;vi) 1-perfluorohexyloctane, (-)-alpha-bisabolol and 2-perfluorohexyloctane, and optionally, squalane;vii) 1-perfluorohexyloctane and chamomile oil; orviii) 1-perfluorohexyloctane, chamomile oil and 2-perfluorohexyloctane,and optionally, squalane.The use according to items 1 to 17, wherein the composition essentiallyconsists of:- 1-perfluorohexyloctane, up to 1.0 % (w / v) (-)-alpha-bisabolol andoptionally, up to 3 % 2-perfluorohexyloctane with respect to the total amountof 1-perfluorohexyloctane and 2-perfluorohexyloctane in the composition; or- 1-perfluorohexyloctane, up to 1.0 % (w / v) chamomile oil (or up to 0.2 %(w / v) chamomile oil, or up to 0.5 % (w / v)) and optionally, up to 3 % 2-perfluorohexyloctane with respect to the total amount of 1-perfluorohexyloctane and 2-perfluorohexyloctane in the composition; or- 1-perfluorohexyloctane, up to 1.0 % (w / v) α-pinene (or up to 0.2 % (w / v) α-pinene) and optionally, up to 3 % 2-perfluorohexyloctane with respect to thetotal amount of 1-perfluorohexyloctane and 2-perfluorohexyloctane in the composition; or- 1-perfluorohexyloctane, up to 1.0 % (w / v) caryophyllene (or up to 0.2 %(w / v) caryophyllene) and optionally, up to 3 % 2-perfluorohexyloctane withrespect to the total amount of 1-perfluorohexyloctane and 2- perfluorohexyloctane in the composition; or- 1-perfluorohexyloctane, up to 1.0 % (w / v), or up to 5.0 % (w / v) guaiazulene(or up to 0.2 % (w / v) guaiazulene) and optionally, up to 3 % 2-perfluorohexyloctane with respect to the total amount of 1-perfluorohexyloctane and 2-perfluorohexyloctane in the composition; or- 1-perfluorohexyloctane, up to 1.0 % (w / v) chamazulene (or up to 0.2 %(w / v) chamazulene) and optionally, up to 3 % 2-perfluorohexyloctane withrespect to the total amount of 1-perfluorohexyloctane and 2- perfluorohexyloctane in the composition; or- 1-perfluorohexyloctane and optionally, up to 3 % 2-perfluorohexyloctanewith respect to the total amount of 1-perfluorohexyloctane and 2- perfluorohexyloctane in the composition; or- 1-perfluorohexyloctane, up to 1.0 % (w / v) (-)-alpha-bisabolol (or up to 0.2 %(w / v) (-)-alpha-bisabolol), up to 10 % (v / v) squalane and optionally, up to 3 %2-perfluorhexyloctane with respect to the total amount of 1-perfluorohexyloctane and 2-perfluorohexyloctane in the composition; or- 1-perfluorohexyloctane, up to 1.0 % (w / v) chamomile oil (or up to 0.2 %(w / v) chamomile oil, or up to 0.5% (w / v) of chamomile oil), up to 10 % (v / v)squalane, and optionally, up to 3 % 2-perfluorohexyloctane with respect to thetotal amount of 1-perfluorohexyloctane and 2-perfluorohexyloctane in the composition; or- 1-perfluorohexyloctane, up to 1.0 % (w / v) α-pinene (or up to 0.2 % (w / v) α-pinene), up to 10 % (v / v) squalane and optionally, up to 3 % 2-perfluorohexyloctane with respect to the total amount of 1-perfluorohexyloctane and 2-perfluorohexyloctane in the composition; or- 1-perfluorohexyloctane, up to 1.0 % (w / v) caryophyllene (or up to 0.2 %(w / v) caryophyllene), up to 10 % (v / v) squalane and optionally, up to 3 % 2-perfluorohexyloctane with respect to the total amount of 1-perfluorohexyloctane and 2-perfluorohexyloctane in the composition; or- 1-perfluorohexyloctane, up to 1.0 % (w / v) guaiazulene (or up to 0.2 % (w / v)guaiazulene), up to 10 % (v / v) squalane, and optionally, up to 3 % 2-perfluorohexyloctane with respect to the total amount of 1-perfluorohexyloctane and 2-perfluorohexyloctane in the composition; or- 1-perfluorohexyloctane, up to 1.0 w / v% chamazulene (or up to 0.2 w / v %chamazulene), up to 10 % (v / v) squalane and optionally, up to 3 % 2-perfluorohexyloctane with respect to the total amount of 1-perfluorohexyloctane and 2-perfluorohexyloctane in the composition; or- 1-perfluorohexyloctane, up to 10 % (v / v) squalane and optionally, up to 3 %2-perfluorohexyloctane with respect to the total amount of 1-perfluorohexyloctane and 2-perfluorohexyloctane in the composition.The use according to item any preceding item, wherein the use comprisescleansing of acneic skin, or skin comprising acne.The use according to item 19, wherein the cleansing comprises the removal ofexcess sebum from acneic skin, preferably wherein the cleansing comprisesthe removal of excess sebum that is obstructing hair follicles on acneic skin.The use according to item any preceding item, wherein the cleansingcomprises the removal, or the reduction of shed excess keratin from a hyperkeratinized area of the skin.The use according to any preceding item, wherein the use comprises thecleansing of sebum-obstructed and / or keratin-obstructed sebaceous glands, pores, or hair follicles of the skin.The use according to any preceding item, wherein the skin is facial skin, orskin located on the face, on the neck, back, chest, or shoulders of a subject, preferably of a subject suffering from acne, acne vulgaris, folliculitis, or keratosis pilaris.The use according to any preceding claim, wherein the use comprises removalof lipophilic cosmetic products from the skin, preferably selected from longlasting or water-proof cosmetic products.The use according to any preceding item, wherein the use comprises a step oftopically applying the composition to the surface of the skin.The use according to item 24, wherein the composition is applied to the skinby means of a device selected from a spray, a roll-on applicator, a sponge, and a wipe.The use according to item 24 or 25, wherein the use comprises a step ofmassaging or rubbing the composition into the skin.The use according to items 24 to 26, wherein the use comprises a subsequentstep of applying an absorbent means onto the skin, and / or a step of removing the remains of the applied composition from the skin with an absorbent means.The use according to item 27, wherein the use comprises an incubation periodbetween the topical application of the composition and the removal of the applied composition, or the remains of the applied composition.A liquid composition comprising a semifluorinated alkane, wherein thesemifluorinated alkane is of the formula F(CF2)n(CH2)mH, wherein n is an integer selected from 4 to 8, and m is an integer selected from 2 to 10.The liquid composition according to item 30, wherein the composition furthercomprises one or more agents selected from the group consisting of (-)-alpha- bisabolol, α-pinene, caryophyllene, guaiazulene, chamomile oil, and chamazulene.The liquid composition according to item 30 or 31, wherein the compositioncomprises chamomile oil.The liquid composition according to item 33, wherein the compositioncomprises up to 1.0- % (w / v) chamomile oil.The liquid composition according to any one of items 30 to 33, wherein thesemifluorinated alkane is selected from F(CF2)4(CH2)5H (F4H5),F(CF2)4(CH2)6H (F4H6), F(CF2)4(CH2)8H (F4H8), F(CF2)4(CH2)10H (F4H10),F(CF2)6(CH2)6H (F6H6), F(CF2)6(CH2)8H (F6H8), and F(CF2)6(CH2)10H (F6H10).The liquid composition according to any one of items 30 to 34, wherein thecomposition comprises at least 50 to 99.9 wt % of the semifluorinated alkane.The liquid composition according to any one of items 30 to 35, wherein thesemifluorinated alkane is 1-perfluorohexyloctane (F6H8).The liquid composition according to item 36, wherein the composition furthercomprises 2-perfluorohexyloctane in an amount of 0.1 to 5 % with respect to the total amount (combined amount) of 1-perfluorohexyloctane and 2- perfluorohexyloctane in the composition.The liquid composition according to any one of items 30 to 37, wherein thecomposition further comprises a non-polar excipient, preferably wherein the non-polar excipient is a liquid excipient fully miscible with the semifluorinated alkane.The use according to item 38, wherein the non-polar excipient is selected fromC10-C40 branched, saturated hydrocarbons and C10-C40 unbranched, saturated hydrocarbons.The use according to items 38 or 39, wherein the non-polar excipient issqualane, optionally wherein the composition comprises up to 50 % (v / v) of squalane.The liquid composition according to any one of items 30 to 40, wherein thecomposition is a solution.The liquid composition according to any one of items 30 to 41, wherein thecomposition has a dynamic viscosity at room temperature of between 1 and 4 mPas.The liquid composition according to any one of items 30 to 42, wherein thecomposition does not comprise a keratolytic agent selected from the groupconsisting of an alpha-hydroxy acid, a beta-hydroxy acid, urea and anycombinations thereof.The liquid composition according to any one of items 30 to 43, wherein thecomposition is not an ointment and / or wherein the composition is free of any one, or combination of:- a solid thickening agent, preferably wherein the solid thickening agent isselected from plant waxes, animal waxes, petroleum derived waxes, solid and semisolid triglycerides, C12-24 fatty acids, C8-18 glycerides, fatty alcohols, fatty alcohols derivatives and any combinations thereof;- an oxidant, e.g. a peroxide, such as benzoyl peroxide, or hydrogen peroxide;- an alpha-hydroxy acid, preferably selected from the group consisting of citricacid; glycolic acid, hydroxycaprylic acid, hydroxycapric acid, lactic acid, malicacid, mandelic acid, phytic acid, and tartaric acid;- a beta-hydroxy acid, preferably selected from the group consisting of salicylicacid, and sodium salicylate; -urea;- a polar solvent, preferably selected from the group consisting of ethylacetate, acetone, an alcohol (e.g. ethanol, isopropanol) and DMSO;- water;- a preservative, preferably selected from the group consisting ofbenzalkonium chloride, chlorhexidine, methylisothiazolinone, methylchlorisothiazolinone, phenoxyethanol, triclosan;- a surfactant, preferably selected from the group consisting of polysorbate(e.g. polysorbate 60), ceteareth, (e.g. any one of ceteareth-6 to ceteareth-25), polyethylene glycol fatty acid esters (e.g. Tefose®63), and sucrose esters (e.g. sucrose stearate, sucrose ester SP70).The liquid composition according to any one of items 30 to 44, wherein thecomposition essentially consists of:ix) the semifluorinated alkane and (-)-alpha-bisabolol;x) the semifluorinated alkane and (-)-alpha-bisabolol, 2-perfluorohexyloctane, and optionally, squalane;xi) the semifluorinated alkane and chamomile oil; orxii) the semifluorinated alkane and chamomile oil, 2-perfluorohexyloctane,and optionally, squalane.The liquid composition according to any one of items 30 to 45, wherein thecomposition essentially consists of:ix) 1-perfluorohexyloctane and (-)-alpha-bisabolol;x) 1-perfluorohexyloctane, (-)-alpha-bisabolol and 2-perfluorohexyloctane, and optionally, squalane;xi) 1-perfluorohexyloctane and chamomile oil; orxii) 1-perfluorohexyloctane, chamomile oil and 2-perfluorohexyloctane,and optionally, squalane.The liquid composition according to any one of items 30 to 46, wherein thecomposition essentially consists of:- 1-perfluorohexyloctane, up to 1.0 % (w / v) (-)-alpha-bisabolol andoptionally, up to 3 % 2-perfluorohexyloctane with respect to the total amountof 1-perfluorohexyloctane and 2-perfluorohexyloctane in the composition; or- 1-perfluorohexyloctane, up to 1.0 % (w / v) chamomile oil (or up to 0.2 %(w / v) chamomile oil, or up to 0.5 % (w / v)) and optionally, up to 3 % 2-perfluorohexyloctane with respect to the total amount of 1-perfluorohexyloctane and 2-perfluorohexyloctane in the composition; or- 1-perfluorohexyloctane, up to 1.0 % (w / v) α-pinene (or up to 0.2 % (w / v) α-pinene) and optionally, up to 3 % 2-perfluorohexyloctane with respect to thetotal amount of 1-perfluorohexyloctane and 2-perfluorohexyloctane in the composition; or- 1-perfluorohexyloctane, up to 1.0 % (w / v) caryophyllene (or up to 0.2 %(w / v) caryophyllene) and optionally, up to 3 % 2-perfluorohexyloctane withrespect to the total amount of 1-perfluorohexyloctane and 2- perfluorohexyloctane in the composition; or- 1-perfluorohexyloctane, up to 1.0 % (w / v), or up to 5.0 % (w / v) guaiazulene(or up to 0.2 % (w / v) guaiazulene) and optionally, up to 3 % 2-perfluorohexyloctane with respect to the total amount of 1-perfluorohexyloctane and 2-perfluorohexyloctane in the composition; or- 1-perfluorohexyloctane, up to 1.0 % (w / v) chamazulene (or up to 0.2 %(w / v) chamazulene) and optionally, up to 3 % 2-perfluorohexyloctane withrespect to the total amount of 1-perfluorohexyloctane and 2- perfluorohexyloctane in the composition; or- 1-perfluorohexyloctane and optionally, up to 3 % 2-perfluorohexyloctanewith respect to the total amount of 1-perfluorohexyloctane and 2- perfluorohexyloctane in the composition; or- 1-perfluorohexyloctane, up to 1.0 % (w / v) (-)-alpha-bisabolol (or up to 0.2 %(w / v) (-)-alpha-bisabolol), up to 10 % (v / v) squalane and optionally, up to 3 %2-perfluorhexyloctane with respect to the total amount of 1-perfluorohexyloctane and 2-perfluorohexyloctane in the composition; or- 1-perfluorohexyloctane, up to 1.0 % (w / v) chamomile oil (or up to 0.2 %(w / v) chamomile oil, or up to 0.5% (w / v) of chamomile oil), up to 10 % (v / v)squalane, and optionally, up to 3 % 2-perfluorohexyloctane with respect to thetotal amount of 1-perfluorohexyloctane and 2-perfluorohexyloctane in the composition; or- 1-perfluorohexyloctane, up to 1.0 % (w / v) α-pinene (or up to 0.2 % (w / v) α-pinene), up to 10 % (v / v) squalane and optionally, up to 3 % 2-perfluorohexyloctane with respect to the total amount of 1-perfluorohexyloctane and 2-perfluorohexyloctane in the composition; or- 1-perfluorohexyloctane, up to 1.0 % (w / v) caryophyllene (or up to 0.2 %(w / v) caryophyllene), up to 10 % (v / v) squalane and optionally, up to 3 % 2-perfluorohexyloctane with respect to the total amount of 1-perfluorohexyloctane and 2-perfluorohexyloctane in the composition; or- 1-perfluorohexyloctane, up to 1.0 % (w / v) guaiazulene (or up to 0.2 % (w / v)guaiazulene), up to 10 % (v / v) squalane, and optionally, up to 3 % 2-perfluorohexyloctane with respect to the total amount of 1-perfluorohexyloctane and 2-perfluorohexyloctane in the composition; or- 1-perfluorohexyloctane, up to 1.0 w / v% chamazulene (or up to 0.2 w / v %chamazulene), up to 10 % (v / v) squalane and optionally, up to 3 % 2-perfluorohexyloctane with respect to the total amount of 1-perfluorohexyloctane and 2-perfluorohexyloctane in the composition; or- 1-perfluorohexyloctane, up to 10 % (v / v) squalane and optionally, up to 3 %2-perfluorohexyloctane with respect to the total amount of 1-perfluorohexyloctane and 2-perfluorohexyloctane in the composition.Use of a composition as defined according to any one of items 1 to 47 as achemical peel, or as a non-water soluble / non-aqueous keratolytic agent, or for keratolysis of the skin.A composition as defined in any one of items 1 to 18 or 30 to 47 for use as amedicament.The composition according to item 49 for use in the cleansing, or for use in thetreatment of the skin of a subject suffering from acne, acne vulgaris, folliculitis, or keratosis pilaris, or any combination thereof.A method of treating or cleansing the skin of a subject suffering from acne,acne vulgaris, folliculitis, keratosis pilaris or any combination thereof,comprising the steps of: i.) topically applying a composition as defined in any one of items 1 to 18or 30 to 47to the skin of the subject; and optionally, ii.) removing the applied composition from the skin with an absorbentmeans.The method according to item 51, comprising an incubation period betweensteps i.) and ii).The method according to items 51 or 52, wherein concomitantly with step ii.)any one or combination of the composition, excess keratin and / or excesssebum and / or cellular debris is also removed from the skin.A cosmetic or medical device comprising a liquid composition as defined initems 1 to 18 or 30 to 47 for the cleansing or applying of said liquidcomposition to the skin of a subject.The cosmetic or medical device of item 54, wherein the device is adapted forapplying the composition to the skin of a subject suffering from acne, acnevulgaris, folliculitis, keratosis pilaris or a combination of these conditions.The cosmetic or medical device according to item 54 or 55, wherein the deviceis a wet wipe, a sponge applicator, or a roll-on applicator.The cosmetic or medical device according to item 54 to 56, wherein the devicecomprises a woven or non-woven substrate comprising any one or combination of cotton, viscose, lyocell, cellulosic fibre pre-wetted with the composition.The cosmetic or medical device according to items 54 to 57, wherein thedevice is also adapted for removing any one or combination of the appliedcomposition, excess keratin and / or excess sebum and / or cellular debris fromthe skin.The cosmetic or medical device according to items 54 to 58, for removing oneor more of sebum, lipid-rich dead skin cells (corneocyte debris), comedogenic cosmetic residues, environmental lipids and / or bacterial lipids.The cosmetic or medical device according to items 59, wherein thecomedogenic cosmetic residues originate from one or more of oil-based cosmetics, (eyeline, lipstick), sunscreens, moisturizers and / or medical ointments.The cosmetic or medical device according to claims 54 to 60, for removinglipophilic substances from the skin. It is particularly suitable as a cleansing agent for removing lipophilic cosmetic products from the skin, the lipophilic cosmetic products preferably selected from long lasting or water-proof cosmetic products.A kit comprising a container for holding a composition as defined in items 1 to18 or 30 to 47 and an application means for applying the composition to theskin of a subject.The kit according to item 62, wherein the application means is a wet wipe thatis pre-wetted with the composition, preferably wherein the wet wipe is adapted for rubbing or massaging of the composition into the skin.64. The kit according to items 62 or 63, wherein the application means is a spongeapplicator, preferably wherein the sponge applicator is adapted for rubbing or massaging the composition into the hyperkeratinized areas of the skin.65. The kit according to items 62 to 64, further comprising a means for removingthe composition, or the remains of the composition in combination with excess keratin and / or excess sebum from the skin, optionally wherein the means is an absorbent substrate or material, e.g. a dry wipe or a pad.The following examples serve to illustrate the invention, however, should not beunderstood as restricting the scope of the invention. DETAILED DESCRIPTION OF THE DRAWINGS Figure 1 depicts the results of in-vivo topical cleansing treatment with 1- perfluorohexyloctane as described in Example 1 with respect to the skin of a minipig. The right side of the photo depicts a ‘treated area’ i.e. to which 1- perfluorohexyloctane has been applied as described in Example 1, with the skin beinguncoloured and clear. The left side of the photo of Figure 1 depicts as a comparison,an untreated area of the skin. Brown-coloured spots are featured on the untreatedskin. EXAMPLES Example 1: Cleansing of skinA minipig was treated in-vivo, topically twice daily on the back with 10g(corresponding to 7.46 mL) of liquid 1-perfluorohexyloctane (F6H8), which wasdistributed over an area of 1000 cm2. Prior to the treatment, the skin at the treatmentsite comprised of visible, brown-coloured spots that may be attributable to shedkeratin accumulated in the pores / glands over time or intra-follicular contamination.The daily treatment of a sample area of skin directly adjacent to an untreated area forcomparison demonstrated after 28 days of treatment, that the topical application of 1-perfluorohexyloctane to the targeted treatment area of the skin resulted in clear,uncoloured skin with substantial removal of the brown-coloured spots from this areaof skin, as shown in Figure 1. In contrast, the brown-coloured spots remained onuntreated skin. Example 2: Preparation of CompositionsThe following compositions of ß-caryophyllene, (-)-alpha-bisabolol, guaiazulene,chamomile oil in F4H5 or F6H8 were prepared by mixing (or dissolving)theserespectively in the specified semifluorinated alkane, or in the liquid vehiclecomprising the specified semifluorinated alkane and liquid excipient (which is fullymiscible with the semifluorinated alkane) to obtain a solution at room temperature.Table 1 - Beta-caryophyllene compositions:Semifluorinated alkane β-Caryophyllene Conc. (mg / ml) F4H5 5.0, 2.0, 1.0, 0.5, 0.2, 0.1F6H8 5.0, 2.0, 1.0, 0.5, 0.2, 0.1Table 2 - (-)-alpha-bisabolol compositions:Semifluorinated alkane (-)-alpha-bisabolol Conc. (mg / ml) F6H8 15, 10, 5, 2.5, 1, 0.5F6H8 + 2-propanol (90:10) 25, 20, 15, 10, 5, 2, 1, 0.5Table 3 - Guaiazulene compositions:Semifluorinated alkane Guaiazulene Conc. (mg / ml) F6H8 5, 4, 3, 2.5, 2, 1, 0.5F6H8 + 2-propanol (90:10) 8, 5, 3, 2.5, 2, 1, 0.5Table 4 - Chamomile oil compositions:Semifluorinated alkane Chamomile Conc. (mg / ml)F6H8 10, 5, 2.5, 2, 1.5, 1, 0.5F6H8 + medium chain triglycerides (95:5 by volume)10, 5, 2.5, 1, 0.5Example 3: Keratolytic effectIn a human psoriasis study, psoriatic plaques, which comprise of, or arehyperkeratinized areas of the skin of psoriasis patients were treated twice daily with20µl F6H8 per 10cm2. After a period of one to two weeks of treatment, it wasobserved that a white layer of scale-like flakes comprising of dead keratin cells wasformed on the surface of the psoriatic plaques. This process of increased scaling (e.g.as determined by standard scale assessment methods in the art, which may forexample be based on visual observation and / or touch by a trained dermatologist) onthe surface of the plaques was observed over a treatment period of about 22 days.Afterwards, this white layer of dead keratin cells detached from the skin surface,leading to an overall decrease in the layer thickness of the psoriatic plaques.This clearly demonstrated that a composition comprising F6H8, applied for use in apathological cornification disorder (hyperkeratosis) of the skin, such as psoriasis,may have beneficial effect, e.g. by effectively removing, or causing removal ordetachment of excess keratin from the surface of the skin and / or from the psoriaticplaque.Example 4 : Removal of lipophilic cosmetic products from the skinA composition essentially consisting of 1-perpfluorohexyloctane is capable ofeffectively removing lipophilic cosmetic products from the skin, in particular thecomposition is suitable as a cleansing agent for cosmetic applications involving long- wearing or waterproof formulations. The performance of composition essentially consisting of 1-perpfluorohexyloctane(CP1) was tested for its capability to remove lipophilic cosmetic products from the skin against 2 commercially available reference compositions, namely Garnier Micellar Cleansing Water (CP2) and Isana Cleansing Oil (CP3). Three different types of lipophilic cosmetic products were selected for testing: a long-lasting lipstick, a waterproof mascara, and a high-coverage foundation. The test procedure involvedapplying the cosmetic products to a defined area of the skin (or forearm), followed bywiping with a cotton pad soaked in the respective cleansing product (CP1, CP2, CP3).The number of wiping motions required to fully remove the cosmetic was recorded. Test 1: Removal of a long-lasting lipstick (Maybelline SuperStay) CP1 was able to completely remove the lipstick after three wiping motions. Incontrast, CP2 required more than five wipes and still left visible residues. CP3achieved full removal after three wipes, comparable to CP1. Test 2: Removal of mascara (Lash Like a Boss) All three cleansing products (CP1, CP2, CP3) were able to remove the mascara after two wiping motions. In this case, the performance of CP1 was equivalent tothat of the reference products CP2 and CP3.Test 3: Removal of foundation (Lancôme Teint Idole Ultra Wear) The cleansing product CP1 removed the foundation effectively with just two wipes. CP2 required three wipes, while CP3 needed as many as five wipes to achieve fullremoval. This indicates a notably superior performance of CP1 of the presentdisclosure, especially in handling high-coverage makeup formulations.These results clearly demonstrate that cleansing product CP1 of the presentdisclosure exhibits excellent efficacy in cleansing the skin of lipophilic cosmeticproducts. Compared to well-established commercial cleansing products (such as C2,Cp3), it performed equally well or better, particularly in the removal of stubborn makeup such as long-lasting lipstick and full-coverage foundation. Due to its highlipophilic cleansing power, CP1 is particularly well-suited for use in cosmeticremovers and facial cleansers targeting waterproof or long-wear makeup.

Claims

1. DRM23P02PC1 Claims 1. Use of a liquid composition comprising 1-perfluorohexyloctane (F6H8)tocleanse skin.

2. The use according to claim 1, wherein the composition further comprisescaryophyllene.

3. The use according to claim 1, wherein the composition further comprises oneor more agents selected from the group consisting of (-)-alpha-bisabolol, α- pinene, guaiazulene, chamomile oil, and chamazulene.

4. The use according to claim 3, wherein the composition comprises up to 1.0- %(w / v) chamomile oil.

5. The use according to any preceding claim, wherein the composition comprisesat least 50 to 99.9 wt % of the 1-perfluorohexyloctane (F6H8).

6. The use according to claim 5, wherein the composition further comprises 2-perfluorohexyloctane in an amount of 0.1 to 5 % with respect to the totalamount (combined amount) of 1-perfluorohexyloctane and 2-perfluorohexyloctane in the composition.

7. The use according to any preceding claim, wherein the composition furthercomprises a non-polar excipient, preferably wherein the non-polar excipient is a liquid excipient fully miscible with the 1-perfluorohexyloctane (F6H8).

8. The use according to claim 7, wherein the non-polar excipient is selected fromC10-C40 branched, saturated hydrocarbons and C10-C40 unbranched,saturated hydrocarbons.

9. The use according to claims 7 or 8, wherein the non-polar excipient issqualane, optionally wherein the composition comprises up to 50 % (v / v) ofsqualane.

10. The use according to any preceding claim, wherein the composition is asolution.

11. The use according to any preceding claim, wherein the composition has adynamic viscosity at room temperature of between 1 and 4 mPas.

12. The use according to any preceding claim, wherein the composition does notcomprise a keratolytic agent selected from the group consisting of an alpha-hydroxy acid, a beta-hydroxy acid, urea and any combinations thereof.

13. The use according to any preceding claim, wherein the composition is not anointment and / or wherein the composition is free of any one, or combinationof: -a solid thickening agent, preferably wherein the solid thickening agent isselected from plant waxes, animal waxes, petroleum derived waxes, solid and semisolid triglycerides, C12-24 fatty acids, C8-18 glycerides, fatty alcohols, fatty alcohols derivatives and any combinations thereof; -an oxidant, e.g. a peroxide, such as benzoyl peroxide, or hydrogen peroxide;- an alpha-hydroxy acid, preferably selected from the group consisting of citricacid; glycolic acid, hydroxycaprylic acid, hydroxycapric acid, lactic acid, malicacid, mandelic acid, phytic acid, and tartaric acid;- a beta-hydroxy acid, preferably selected from the group consisting of salicylicacid, and sodium salicylate; -urea; -a polar solvent, preferably selected from the group consisting of ethylacetate, acetone, an alcohol (e.g. ethanol, isopropanol) and DMSO;- water;- a preservative, preferably selected from the group consisting ofbenzalkonium chloride, chlorhexidine, methylisothiazolinone, methylchlorisothiazolinone, phenoxyethanol, triclosan; -a surfactant, preferably selected from the group consisting of polysorbate(e.g. polysorbate 60), ceteareth, (e.g. any one of ceteareth-6 to ceteareth-25), polyethylene glycol fatty acid esters (e.g. Tefose®63), and sucrose esters (e.g. sucrose stearate, sucrose ester SP70).

14. The use according to any preceding claim, wherein the composition essentiallyconsists of: i) 1-perfluorohexyloctane and (-)-alpha-bisabolol;ii) 1-perfluorohexyloctane, (-)-alpha-bisabolol and 2-perfluorohexyloctane, and optionally, squalane;iii) 1-perfluorohexyloctane and chamomile oil; oriv) 1-perfluorohexyloctane, chamomile oil and 2-perfluorohexyloctane,and optionally, squalane.

15. The use according to claims 1 to 14, wherein the composition essentiallyconsists of: -1-perfluorohexyloctane, up to 1.0 % (w / v) (-)-alpha-bisabolol andoptionally, up to 3 % 2-perfluorohexyloctane with respect to the total amountof 1-perfluorohexyloctane and 2-perfluorohexyloctane in the composition; or- 1-perfluorohexyloctane, up to 1.0 % (w / v) chamomile oil (or up to 0.2 %(w / v) chamomile oil, or up to 0.5 % (w / v)) and optionally, up to 3 % 2-perfluorohexyloctane with respect to the total amount of 1-perfluorohexyloctane and 2-perfluorohexyloctane in the composition; or- 1-perfluorohexyloctane, up to 1.0 % (w / v) α-pinene (or up to 0.2 % (w / v) α-pinene) and optionally, up to 3 % 2-perfluorohexyloctane with respect to thetotal amount of 1-perfluorohexyloctane and 2-perfluorohexyloctane in the composition; or -1-perfluorohexyloctane, up to 1.0 % (w / v) caryophyllene (or up to 0.2 %(w / v) caryophyllene) and optionally, up to 3 % 2-perfluorohexyloctane withrespect to the total amount of 1-perfluorohexyloctane and 2-perfluorohexyloctane in the composition; or -1-perfluorohexyloctane, up to 1.0 % (w / v), or up to 5.0 % (w / v) guaiazulene(or up to 0.2 % (w / v) guaiazulene) and optionally, up to 3 % 2-perfluorohexyloctane with respect to the total amount of 1-perfluorohexyloctane and 2-perfluorohexyloctane in the composition; or- 1-perfluorohexyloctane, up to 1.0 % (w / v) chamazulene (or up to 0.2 %(w / v) chamazulene) and optionally, up to 3 % 2-perfluorohexyloctane withrespect to the total amount of 1-perfluorohexyloctane and 2- perfluorohexyloctane in the composition; or- 1-perfluorohexyloctane and optionally, up to 3 % 2-perfluorohexyloctanewith respect to the total amount of 1-perfluorohexyloctane and 2- perfluorohexyloctane in the composition; or- 1-perfluorohexyloctane, up to 1.0 % (w / v) (-)-alpha-bisabolol (or up to 0.2 %(w / v) (-)-alpha-bisabolol), up to 10 % (v / v) squalane and optionally, up to 3 %2-perfluorhexyloctane with respect to the total amount of 1-perfluorohexyloctane and 2-perfluorohexyloctane in the composition; or- 1-perfluorohexyloctane, up to 1.0 % (w / v) chamomile oil (or up to 0.2 %(w / v) chamomile oil, or up to 0.5% (w / v) of chamomile oil), up to 10 % (v / v)squalane, and optionally, up to 3 % 2-perfluorohexyloctane with respect to thetotal amount of 1-perfluorohexyloctane and 2-perfluorohexyloctane in the composition; or- 1-perfluorohexyloctane, up to 1.0 % (w / v) α-pinene (or up to 0.2 % (w / v) α-pinene), up to 10 % (v / v) squalane and optionally, up to 3 % 2-perfluorohexyloctane with respect to the total amount of 1-perfluorohexyloctane and 2-perfluorohexyloctane in the composition; or- 1-perfluorohexyloctane, up to 1.0 % (w / v) caryophyllene (or up to 0.2 %(w / v) caryophyllene), up to 10 % (v / v) squalane and optionally, up to 3 % 2-perfluorohexyloctane with respect to the total amount of 1-perfluorohexyloctane and 2-perfluorohexyloctane in the composition; or- 1-perfluorohexyloctane, up to 1.0 % (w / v) guaiazulene (or up to 0.2 % (w / v)guaiazulene), up to 10 % (v / v) squalane, and optionally, up to 3 % 2-perfluorohexyloctane with respect to the total amount of 1-perfluorohexyloctane and 2-perfluorohexyloctane in the composition; or- 1-perfluorohexyloctane, up to 1.0 w / v% chamazulene (or up to 0.2 w / v %chamazulene), up to 10 % (v / v) squalane and optionally, up to 3 % 2-perfluorohexyloctane with respect to the total amount of 1-perfluorohexyloctane and 2-perfluorohexyloctane in the composition; or -1-perfluorohexyloctane, up to 10 % (v / v) squalane and optionally, up to 3 %2-perfluorohexyloctane with respect to the total amount of 1-perfluorohexyloctane and 2-perfluorohexyloctane in the composition.

16. The use according to claim any preceding claim, wherein the use comprisescleansing of acneic skin, or skin comprising acne.

17. The use according to claim 16, wherein the cleansing comprises the removal ofexcess sebum from acneic skin, preferably wherein the cleansing comprisesthe removal of excess sebum that is obstructing hair follicles on acneic skin.

18. The use according to claim any preceding claim, wherein the cleansingcomprises the removal, or the reduction of shed excess keratin from ahyperkeratinized area of the skin.

19. The use according to any preceding claim, wherein the use comprises thecleansing of sebum-obstructed and / or keratin-obstructed sebaceous glands,pores, or hair follicles of the skin.

20. The use according to any preceding claim, wherein the skin is facial skin, orskin located on the face, on the neck, back, chest, or shoulders of a subject,preferably of a subject suffering from acne, acne vulgaris, folliculitis, orkeratosis pilaris.

21. The use according to any preceding claim, wherein the use comprises removalof lipophilic cosmetic products from the skin, preferably selected from longlasting or water-proof cosmetic products.

22. The use according to any preceding claim, wherein the use comprises a step oftopically applying the composition to the surface of the skin.

23. The use according to claim 22, wherein the composition is applied to the skinby means of a device selected from a spray, a roll-on applicator, a sponge, and a wipe.

24. The use according to claim 22 or 23, wherein the use comprises a step ofmassaging or rubbing the composition into the skin.

25. The use according to claims 22 to 24, wherein the use comprises a subsequentstep of applying an absorbent means onto the skin, and / or a step of removingthe remains of the applied composition from the skin with an absorbent means.

26. The use according to claim 25, wherein the use comprises an incubationperiod between the topical application of the composition and the removal ofthe applied composition, or the remains of the applied composition.

27. A liquid composition comprising 1-perflurohexyloctane (F6H8) and optionallycaryophyllene, and / or one or more agents selected from the group consisting of (-)-alpha-bisabolol, α-pinene, guaiazulene, chamomile oil, and chamazulene.

28. Use of a composition as defined according to any one of claims 1 to 27 as achemical peel, or as a non-water soluble / non-aqueous keratolytic agent, or forkeratolysis of the skin.

29. A composition as defined in any one of claims 1 to 15 for use as a medicament.

30. The composition according to claim 29 for use in the cleansing, or for use inthe treatment of the skin of a subject suffering from acne, acne vulgaris, folliculitis, or keratosis pilaris, or any combination thereof.

31. A method of treating or cleansing the skin of a subject suffering from acne,acne vulgaris, folliculitis, keratosis pilaris or any combination thereof,comprising the steps of: a. topically applying a composition as defined in any one of claims 1 to 15to the skin of the subject; and optionally,b. removing the applied composition from the skin with an absorbentmeans.

32. The method according to claim 31 comprising an incubation period betweensteps i.) and ii).

33. The method according to claims 31 or 32 wherein concomitantly with step ii.)any one or combination of the composition, excess keratin and / or excesssebum and / or cellular debris is also removed from the skin.

34. A cosmetic or medical device comprising a liquid composition as defined inclaims 1 to 15 for the cleansing or applying of said liquid composition to theskin of a subject.

35. The cosmetic or medical device of claim 34, wherein the device is adapted forapplying the composition to the skin of a subject suffering from acne, acnevulgaris, folliculitis, keratosis pilaris or a combination of these conditions.

36. The cosmetic or medical device according to claim 34 or 35, wherein thedevice is a wet wipe, a sponge applicator, or a roll-on applicator.

37. The cosmetic or medical device according to claim 34 to 36, wherein thedevice comprises a woven or non-woven substrate comprising any one orcombination of cotton, viscose, lyocell, cellulosic fibre pre-wetted with thecomposition.

38. The cosmetic or medical device according to claims 34 to 37, wherein thedevice is also adapted for removing any one or combination of the applied composition, excess keratin and / or excess sebum and / or cellular debris fromthe skin.

39. The cosmetic or medical device according to claims 34 to 38, for removing oneor more of sebum, lipid-rich dead skin cells (corneocyte debris), comedogenic cosmetic residues, environmental lipids and / or bacterial lipids.

40. The cosmetic or medical device according to claims 39, wherein thecomedogenic cosmetic residues originate from one or more of oil-based cosmetics, (eyeline, lipstick), sunscreens, moisturizers and / or medical ointments.

41. The cosmetic or medical device according to claims 34 to 37, for removinglipophilic substances from the skin. It is particularly suitable as a cleansing agent for removing lipophilic cosmetic products from the skin, the lipophiliccosmetic products preferably selected from long lasting or water-proof cosmetic products.

42. A kit comprising a container for holding a composition as defined in claims 1to 15 and an application means for applying the composition to the skin of a subject.

43. The kit according to claim 42, wherein the application means is a wet wipethat is pre-wetted with the composition, preferably wherein the wet wipe is adapted for rubbing or massaging of the composition into the skin.

44. The kit according to claims 42 or 43, wherein the application means is asponge applicator, preferably wherein the sponge applicator is adapted forrubbing or massaging the composition into the hyperkeratinized areas of the skin.

45. The kit according to claims 42 to 44, further comprising a means for removingthe composition, or the remains of the composition in combination with excess keratin and / or excess sebum from the skin, optionally wherein the means isan absorbent substrate or material, e.g. a dry wipe or a pad.

Images